SCHEMBL6566912

SCHEMBL6566912

CCCCCc1ccc(O)c(OC)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.69
CYP1A2 P05177 3/20 0.69
CYP3A4 P08684 3/20 0.69
CYP2C8 P10632 3/20 0.69
CYP2C9 P11712 3/20 0.69
CYP2B6 P20813 3/20 0.69
CYP2C19 P33261 3/20 0.69
TAAR1 Q96RJ0 2/20 0.67
TSHR P16473 1/20 0.67
MAPK1 P28482 1/20 0.67
LMNA P02545 1/20 0.65
GLA P06280 1/20 0.65
PTPN1 P18031 1/20 0.63
LTA4H P09960 2/20 0.63
TRPV1 Q8NER1 2/20 0.63
CYP2E1 P05181 1/20 0.63
ALOX5 P09917 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2A6 P11509 1/20 0.63
PPARG P37231 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28234392 0.98 HTR1A (0.72) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL7246840 0.98 HTR1A (0.72) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL9485313 0.98 HTR1A (0.72) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL16609989 0.98 HTR1A (0.72) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL6923070 0.98 HTR1A (0.72) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL31710801 0.95 TAAR1 (0.69) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL677607 0.95 TAAR1 (0.69) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL9281549 0.93 TAAR1 (0.76) CYP3A4TAAR1TSHRMAPK1LMNA
SCHEMBL23370746 0.90 HTR1A (0.87) HTR1ACYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL5072123 0.89 TAAR1 (0.76) CYP1A2CYP3A4CYP2C8CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3571180-B1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF UNIV LEUVEN KATH (BE) 2024-12-18 EP disclosed
US-20210070684-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2021-03-11 US disclosed
EP-3571180-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF Katholieke Universiteit Leuven (BE) 2019-11-27 EP disclosed
WO-2018134427-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2018-07-26 WO disclosed
US-8871861-B2 Silicone compound, photocurable liquid ink using the silicone compound, and method of manufacturing the ink RICOH COMPANY, LTD. (JP) 2014-10-28 US disclosed
US-20120283378-A1 A SILICONE COMPOUND, PHOTOCURABLE LIQUID INK USING THE SILICONE COMPOUND, AND METHOD OF MANUFACTURING THE INK RICOH COMPANY, LTD., (JP) 2012-11-08 US disclosed
EP-2520579-A2 A silicone compound, photocurable liquid ink using the silicone compound, and method of manufacturing the ink Ricoh Company, Ltd. (JP) 2012-11-07 EP disclosed
CN-1188258-C Process for high polymer synthesis to phenol compounds and the like and use thereof SHOWA DENKO KK (JP) 2005-02-09 CN disclosed
EP-1450758-A2 COSMETIC COMPOSITIONS USING POLYETHER SILOXANE COPOLYMER NETWORK COMPOSITIONS GENERAL ELECTRIC COMPANY (US) 2004-09-01 EP disclosed
WO-2002092048-A2 COSMETIC COMPOSITIONS USING POLYETHER SILOXANE COPOLYMER NETWORK COMPOSITIONS GENERAL ELECTRIC COMPANY (US) 2002-11-21 WO disclosed
CN-1312150-A Process for high polymer synthesis to phenol compounds and the like and use thereof SHOWA DENKO KK (JP) 2001-09-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070684-A1 PRODUCTION OF HIGHLY PURE META,META-COUPLED BIS(4-ALKYLPHENOL) DERIVATIVES AND USES THEREOF MMS19, PCBP1, PBRM1 HTR1A 2184/4885CYP1A2 88/4885CYP3A4 48/4885
US-20120283378-A1 A SILICONE COMPOUND, PHOTOCURABLE LIQUID INK USING THE SILICONE COMPOUND, AND METHOD OF MANUFACTURING THE INK DOT1L, L3MBTL3, KDM7A HTR1A 2153/4885CYP1A2 2337/4885CYP3A4 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.